Max Nisen, Columnist

AbbVie Must Escape the Shadow of Humira's Decline

Solid near-term results can’t erase doubts about the future.

April 26, 2018 at 3:03 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

A monitor displays signage for Pfizer Inc., Eli Lilly and Co., AbbVie Inc. and Merck & Co Inc. on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Monday, March 13, 2017. U.S. stocks held steady as they kicked off a week dominated by central-bank updates including the Federal Reserve's rate decision.Photographer: Bloomberg/Bloomberg

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

There’s a shadow hanging over AbbVie Inc., even on days when it shines.

The maker of the blockbuster inflammation drug Humira is doing great by many metrics, thanks to that medicine’s success. AbbVie released first-quarter results on Thursday that beat analyst earnings and revenue expectations and raised its full-year EPS guidance. Adjusted earnings grew a stunning 46 percent from the same period last year.